Sangamo Regains Giroctocogene Fitelparvovec Rights
This is a news story, published by Yahoo Finance, that relates primarily to SGMO news.
SGMO news
For more SGMO news, you can click here:
more SGMO newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Hemophilia Gene Therapy Pact. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest article Sangamo Therapeutics Stock Plunges news, Pfizer Inc news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
investigational gene therapy product candidateBenzinga
•Sangamo Therapeutics, Inc. (SGMO) regains development and commercialization rights to giroctocogene fitelparvovec
74% Informative
Sangamo Therapeutics, Inc. (NASDAQ: SGMO ) regained the development and commercialization rights to giroctocogene fitelparvovec.
Pfizer decided to terminate the global collaboration and license agreement between the parties.
Sangamo intends to explore all options to advance the program, including seeking a potential new collaboration partner.
VR Score
66
Informative language
63
Neutral language
30
Article tone
formal
Language
English
Language complexity
75
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
8
Source diversity
1
Affiliate links
no affiliate links